Jefferies Group's BIIB Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 32,513 shares of Biogen Inc. (BIIB) worth $5.72 M, representing 0.03% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in BIIB, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 40,820 shares. Largest reduction occurred in Q1 2025, reducing 33,853 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Biogen (BIIB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Biogen (BIIB) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +1,913 | Add 6.25% | 32,513 | $175.99 |
| Q3 2025 | -6,517 | Reduce 17.56% | 30,600 | $140.08 |
| Q2 2025 | -12,877 | Reduce 25.76% | 37,117 | $125.59 |
| Q1 2025 | -33,853 | Reduce 40.37% | 49,994 | $136.84 |
| Q4 2024 | +40,820 | Add 94.87% | 83,847 | $152.92 |
| Q3 2024 | +39,719 | Add 1200.70% | 43,027 | $193.84 |
| Q2 2024 | -576 | Reduce 14.83% | 3,308 | $231.82 |
| Q1 2024 | -45 | Reduce 1.15% | 3,884 | $215.63 |
| Q4 2023 | -5,561 | Reduce 58.60% | 3,929 | $258.77 |
| Q3 2023 | +6,021 | Add 173.57% | 9,490 | $257.01 |
| Q2 2023 | -155 | Reduce 4.28% | 3,469 | $284.85 |
| Q1 2023 | -17,818 | Reduce 83.10% | 3,624 | $278.03 |
| Q4 2022 | +21,442 | New Buy | 21,442 | $276.92 |
| Q2 2019 | -4,114 | Sold Out | 0 | $0.00 |
| Q1 2019 | -7,412 | Reduce 64.31% | 4,114 | $236.27 |
| Q4 2018 | +643 | Add 5.91% | 11,526 | $300.88 |
| Q3 2018 | -1,192 | Reduce 9.87% | 10,883 | $353.30 |
| Q2 2018 | +5,744 | Add 90.73% | 12,075 | $290.27 |
| Q1 2018 | +4,794 | Add 311.91% | 6,331 | $273.73 |
| Q4 2017 | +1,537 | New Buy | 1,537 | $318.80 |
| Q2 2017 | -1,716 | Sold Out | 0 | $0.00 |
| Q1 2017 | +1,716 | New Buy | 1,716 | $273.31 |
Jefferies Group's Biogen Investment FAQs
Jefferies Group first purchased Biogen Inc. (BIIB) in Q1 2017, acquiring 1,716 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Biogen Inc. (BIIB) for 22 quarters since Q1 2017.
Jefferies Group's largest addition to Biogen Inc. (BIIB) was in Q4 2024, adding 83,847 shares worth $12.82 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 32,513 shares of Biogen Inc. (BIIB), valued at approximately $5.72 M.
As of the Q4 2025 filing, Biogen Inc. (BIIB) represents approximately 0.03% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Biogen Inc. (BIIB) was 83,847 shares, as reported at the end of Q4 2024.